DE3590080T - 1α-Hydroxyvitamin D↓2↓-Analogverbindungen und Verfahren zu deren Herstellung - Google Patents

1α-Hydroxyvitamin D↓2↓-Analogverbindungen und Verfahren zu deren Herstellung

Info

Publication number: DE3590080T
Authority: DE; Germany
Prior art keywords: compound; compounds; vitamin; mixture; product
Prior art date: 1984-03-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

DE19853590080

Other languages

German (de)

English (en)

Other versions

DE3590080C2 (fr

Inventor

Hector F. Deluca

Heinrich K. Madison Wis. Schnoes

Rafal R. Warschau/Warszawa Sicinski

Yoko Delmar N.Y. Tanaka

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wisconsin Alumni Research Foundation

Original Assignee

Wisconsin Alumni Research Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-03-05

Filing date

1985-01-22

Publication date

1986-02-20

1985-01-22 Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation

1986-02-20 Publication of DE3590080T publication Critical patent/DE3590080T/de

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims description 85
238000000034 method Methods 0.000 title description 17
OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 title 1
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
239000001257 hydrogen Substances 0.000 claims 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
239000000203 mixture Substances 0.000 description 25
239000000047 product Substances 0.000 description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 13
241000700159 Rattus Species 0.000 description 13
239000000243 solution Substances 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
229930003316 Vitamin D Natural products 0.000 description 11
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 11
238000001819 mass spectrum Methods 0.000 description 11
235000019166 vitamin D Nutrition 0.000 description 11
239000011710 vitamin D Substances 0.000 description 11
229940046008 vitamin d Drugs 0.000 description 11
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
239000011575 calcium Substances 0.000 description 10
229910052791 calcium Inorganic materials 0.000 description 10
150000003710 vitamin D derivatives Chemical class 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
230000004071 biological effect Effects 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
239000011734 sodium Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
206010047626 Vitamin D Deficiency Diseases 0.000 description 6
239000002904 solvent Substances 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 5
238000010828 elution Methods 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
RQOCXCFLRBRBCS-LNOGQBHPSA-N (3s,9s,10r,13r,14r,17r)-10,13-dimethyl-17-[(e,2r)-6-methylhept-3-en-2-yl]-2,3,4,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/CC(C)C)CC[C@H]33)C)C3=CC=C21 RQOCXCFLRBRBCS-LNOGQBHPSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
230000033558 biomineral tissue development Effects 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
230000037213 diet Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
238000003797 solvolysis reaction Methods 0.000 description 4
CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
210000002303 tibia Anatomy 0.000 description 4
238000011282 treatment Methods 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
-1 vitamin D compounds Chemical class 0.000 description 4
OMIHGPLIXGGMJB-UHFFFAOYSA-N 7-oxabicyclo[4.1.0]hepta-1,3,5-triene Chemical compound C1=CC=C2OC2=C1 OMIHGPLIXGGMJB-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
150000002009 diols Chemical class 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000005805 hydroxylation reaction Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
150000003722 vitamin derivatives Chemical class 0.000 description 3
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
DYDLBPLCFQGRIY-UHFFFAOYSA-N 5-butyl-5-(1-butyl-5-methylcyclohexa-2,4-dien-1-yl)sulfonyl-1-methylcyclohexa-1,3-diene Chemical compound C1C(C)=CC=CC1(CCCC)S(=O)(=O)C1(CCCC)CC(C)=CC=C1 DYDLBPLCFQGRIY-UHFFFAOYSA-N 0.000 description 2
206010006956 Calcium deficiency Diseases 0.000 description 2
229910004373 HOAc Inorganic materials 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
238000010504 bond cleavage reaction Methods 0.000 description 2
230000018678 bone mineralization Effects 0.000 description 2
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000033444 hydroxylation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
244000144977 poultry Species 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
229910001023 sodium amalgam Inorganic materials 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000003457 sulfones Chemical class 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
239000003643 water by type Substances 0.000 description 2
JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 description 1
WVWZCGAJFDYQCR-UHFFFAOYSA-N 3-methylbutylsulfonylbenzene Chemical compound CC(C)CCS(=O)(=O)C1=CC=CC=C1 WVWZCGAJFDYQCR-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
235000021318 Calcifediol Nutrition 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
208000000038 Hypoparathyroidism Diseases 0.000 description 1
NGEVNHYPVVOXPB-UHFFFAOYSA-N Isopyrocalciferolacetat Natural products C1C(OC(C)=O)CCC2(C)C(CCC3(C(C(C)C=CC(C)C(C)C)CCC33)C)C3=CC=C21 NGEVNHYPVVOXPB-UHFFFAOYSA-N 0.000 description 1
240000007049 Juglans regia Species 0.000 description 1
235000009496 Juglans regia Nutrition 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
NGEVNHYPVVOXPB-SPRPGQCRSA-N O-acetyl-ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@@H]2C3=CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)C NGEVNHYPVVOXPB-SPRPGQCRSA-N 0.000 description 1
206010031240 Osteodystrophy Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010073771 Soybean Proteins Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
NGEVNHYPVVOXPB-RZZBNZQCSA-N [(3s,9s,10r,13r,14r,17r)-17-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1[C@@H](OC(C)=O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 NGEVNHYPVVOXPB-RZZBNZQCSA-N 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000004094 calcium homeostasis Effects 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
238000001816 cooling Methods 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical class [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
PTVDYARBVCBHSL-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu] PTVDYARBVCBHSL-UHFFFAOYSA-N 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
150000001993 dienes Chemical class 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000003278 egg shell Anatomy 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
239000008267 milk Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
208000007442 rickets Diseases 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940001941 soy protein Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003431 steroids Chemical group 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
235000020234 walnut Nutrition 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE19853590080 1984-03-05 1985-01-22 1α-Hydroxyvitamin D↓2↓-Analogverbindungen und Verfahren zu deren Herstellung Pending DE3590080T (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US58616084A	1984-03-05	1984-03-05

Publications (1)

Publication Number	Publication Date
DE3590080T true DE3590080T (de)	1986-02-20

Family

ID=24344548

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE19853590080 Pending DE3590080T (de)	1984-03-05	1985-01-22	1α-Hydroxyvitamin D↓2↓-Analogverbindungen und Verfahren zu deren Herstellung
DE3590080A Expired - Lifetime DE3590080C2 (fr)	1984-03-05	1985-01-22

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE3590080A Expired - Lifetime DE3590080C2 (fr)	1984-03-05	1985-01-22

Country Status (12)

Country	Link
JP (1)	JPH064536B2 (fr)
AU (1)	AU584071B2 (fr)
BE (1)	BE901879A (fr)
CH (1)	CH667658A5 (fr)
DE (2)	DE3590080T (fr)
DK (1)	DK153145C (fr)
FR (1)	FR2560597B1 (fr)
GB (1)	GB2155478B (fr)
IE (1)	IE57951B1 (fr)
IL (1)	IL74168A (fr)
NL (1)	NL8520021A (fr)
WO (1)	WO1985003939A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8915770D0 (en) *	1989-07-10	1989-08-31	Leo Pharm Prod Ltd	Chemical compounds
IN171426B (fr) *	1990-02-14	1992-10-10	Wisconsin Alumni Res Found
US5030772A (en) *	1990-02-14	1991-07-09	Deluca Hector F	Process for preparing vitamin D2 compounds and the corresponding 1 α-hydroxylated derivatives
US5260290A (en) *	1990-02-14	1993-11-09	Wisconsin Alumni Research Foundation	Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3907843A (en) *	1974-06-14	1975-09-23	Wisconsin Alumni Res Found	1{60 -Hydroxyergocalciferol and processes for preparing same
US3880894A (en) *	1974-05-24	1975-04-29	Wisconsin Alumni Res Found	1,25-Dihydroxyergocalciferol
US4195027A (en) *	1978-01-16	1980-03-25	Wisconsin Alumni Research Foundation	Process for preparing 1α-hydroxylated compounds
US4206131A (en) *	1978-06-19	1980-06-03	The Upjohn Company	Compounds and process
US4267117A (en) *	1978-06-19	1981-05-12	The Upjohn Company	Compounds and process
US4360471A (en) *	1981-12-11	1982-11-23	Wisconsin Alumni Research Foundation	23-Dehydro-25-hydroxyvitamin D3
US4508651A (en) *	1983-03-21	1985-04-02	Hoffmann-La Roche Inc.	Synthesis of 1α,25-dihydroxyergocalciferol
AU587174B2 (en) *	1984-01-30	1989-08-10	Wisconsin Alumni Research Foundation	1a, 25-dihydroxy-22z-dehydrovitamin d compound

1985
- 1985-01-22 NL NL8520021A patent/NL8520021A/nl unknown
- 1985-01-22 DE DE19853590080 patent/DE3590080T/de active Pending
- 1985-01-22 CH CH4779/85A patent/CH667658A5/de not_active IP Right Cessation
- 1985-01-22 WO PCT/US1985/000097 patent/WO1985003939A1/fr active Application Filing
- 1985-01-22 AU AU38895/85A patent/AU584071B2/en not_active Ceased
- 1985-01-22 DE DE3590080A patent/DE3590080C2/de not_active Expired - Lifetime
- 1985-01-22 JP JP60500734A patent/JPH064536B2/ja not_active Expired - Lifetime
- 1985-01-25 IL IL74168A patent/IL74168A/xx not_active IP Right Cessation
- 1985-03-01 IE IE520/85A patent/IE57951B1/en not_active IP Right Cessation
- 1985-03-04 GB GB08505486A patent/GB2155478B/en not_active Expired
- 1985-03-04 FR FR8503135A patent/FR2560597B1/fr not_active Expired
- 1985-03-05 BE BE0/214606A patent/BE901879A/fr not_active IP Right Cessation
- 1985-11-04 DK DK506985A patent/DK153145C/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
FR2560597A1 (fr)	1985-09-06
AU584071B2 (en)	1989-05-18
IL74168A0 (en)	1985-04-30
DK506985D0 (da)	1985-11-04
GB2155478B (en)	1987-12-16
BE901879A (fr)	1985-07-01
CH667658A5 (de)	1988-10-31
IE57951B1 (en)	1993-05-19
NL8520021A (nl)	1986-02-03
AU3889585A (en)	1985-09-24
WO1985003939A1 (fr)	1985-09-12
DK506985A (da)	1985-11-06
GB8505486D0 (en)	1985-04-03
JPH064536B2 (ja)	1994-01-19
DK153145B (da)	1988-06-20
DK153145C (da)	1988-10-31
IL74168A (en)	1988-11-15
IE850520L (en)	1985-09-05
DE3590080C2 (fr)	1992-08-06
FR2560597B1 (fr)	1987-12-04
GB2155478A (en)	1985-09-25
JPS61501447A (ja)	1986-07-17

Publication	Publication Date	Title
DE69006052T2 (de)	1994-05-05	19-Nor-Vitamin-D-Derivate.
US5840938A (en)	1998-11-24	20(S)-25-hydroxy vitamin D compounds
US5532391A (en)	1996-07-02	Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
DE69819312T2 (de)	2004-07-29	2-alkyl-19-nor-vitamin d-verbindungen
DE3248900C2 (fr)	1990-12-13
DE2012167C2 (de)	1982-09-23	25-Hydroxycholecalciferol-hydrat und Verfahren sowie Zwischenprodukte zu seiner Herstellung
US4689180A (en)	1987-08-25	1α,25-dihydroxy-22Z-dehydroxyvitamin D compound
EP0663902B1 (fr)	1998-03-11	Derives d'acide carboxylique 25 de la serie de la vitamine d, preparations pharmaceutiques contenant ces derives et leur utilisation pour preparer des medicaments
DE69233074T2 (de)	2004-03-18	Verfahren zur Herstellung von 1-alpha-24-dihydroxy-Vitamin D2
WO1993012081A1 (fr)	1993-06-24	Derives de vitamine d a substitution 20-methyle
DE3590232C2 (de)	1992-09-17	1,24-Dihydroxy- 22-Vitamin D3-Derivate, diese enthaltende Arzneimittel sowie Cholesterinderivate alsZwischenprodukte
DE69109006T2 (de)	1995-08-31	HOMOLOGIERTE VITAMIN-D2-VERBINDUNGEN UND KORRESPONDIERENDE 1alpha-HYDROXYLIERTE VERBINDUNGEN.
DE69325253T2 (de)	1999-12-02	1alpha,24(s)-dihydroxy vitamin d2, seine synthese und verwendung
DE3490215C2 (fr)	1991-07-25
US4505906A (en)	1985-03-19	Hydroxyvitamin D2 isomers
CH650240A5 (de)	1985-07-15	24,24-difluor-1alpha,25-dihydroxycholecalciferol.
US4719204A (en)	1988-01-12	Fowl bone mineralization with 28-NOR 1α-hydroxyvitamin D2 analogs
DE3590080C2 (fr)	1992-08-06
DE69318142T2 (de)	1998-09-17	1 alpha-HYDROXY-24-(EPI)-VITAMIN D4
DE3590021C2 (de)	1992-09-10	1alpha-Hydroxyvitamin D-Derivat und dieses enthaltendes Arzneimittel
CH656389A5 (de)	1986-06-30	Zwischenprodukte zur herstellung von vitamin d(3)-derivaten.
US5354744A (en)	1994-10-11	Side chain unsaturated 1 alpha-hydroxyvitamin D analogs
DE3590020C2 (de)	1995-03-09	In der Seitenkette ungesättigte 1-Hydroxyvitamin D-Verbindungen
DE2822752A1 (de)	1978-11-30	1 alpha -hydroxy-24-dehydrovitamin d tief 3
DE69108319T2 (de)	1995-07-27	Verfahren zur herstellung von vitamin-d2-verbindungen und ihrer 1-alpha hydrogenierten derivate.

DE3590080T - 1&alpha;-Hydroxyvitamin D&darr;2&darr;-Analogverbindungen und Verfahren zu deren Herstellung - Google Patents